Axion BioSystems, an Atlanta, GA-based manufacturer of a multiwell microelectrode array (MEA) platform, closed a $6m equity financing.
The round was led by GRA Venture Fund.
The company intends to use the funds to accelerate the growth of its core life science instrumentation product line.
Founded in 2008 and led by CEO Tom O’Brien, Axion BioSystems is a life science instrumentation company that develops the Maestro high-throughput microelectrode array (MEA) platform for cellular analysis, which allows researchers to recreate brain activity and heartbeats.
In conjunction with the funding, Jay Teich, former CEO of Seahorse Bioscience, a company focused on cell metabolism that was sold to Agilent Technologies in November 2015, will join Axion’s Board of Directors.